Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phospholipidated rhCu/Zn SOD to reduce myocardial reperfusion injury
CTR20160764Phase 2Completed
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of phospholipidated recombinant human copper zinc superoxide dismutase in myocardial infarction (MI), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started May 2019; status: completed.
02
Drugs
phospholipidated recombinant human copper zinc superoxide dismutase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20160764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160764.